Table 3.
Clinical and histopathological characteristics and response to surgery of MTCs presenting with preoperative serum Ctn levels above 500 pg/mL.
| ID | Sex | Age (yrs) | Preoperative markers | Tumor size (mm) | Tumor capsule | ETE | Vascular invasion | Lymph nodes involvement | AJCC TNM 8th ed. staging | Clinical setting | Postoperative markers | Cured | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ctn (pg/mL) | CEA (ng/mL) | Ctn (pg/mL) | CEA (ng/mL) | |||||||||||
| #29 | F | 77 | 535 | 52.4 | 11 | No | No | No | No | pT1b, N0, M0 | sMTC | 8.7 | 2.5 | No |
| #23 | F | 77 | 654 | N/A | 20 | No | No | Yes | No | pT1b, N0, M0 | sMTC | 348 | 34.3 | No |
| #24 | M | 55 | 787 | 41.1 | 35 | No | Yes | Yes | Yes | pT4a(m), N1b, M0 | sMTC | 92.6 | 16.3 | No |
| #30 | M | 31 | 996 | 18.1 | 8 | No | No | Yes | Yes | pT1a(m), N1b, M0 | sMTC | 320 | 6.9 | No |
| #21 | M | 59 | 1132 | 88.0 | 33 | Yes | No | No | No | pT2, N0, M0 | sMTC | < 2 | 3.8 | Yes |
| #10 | M | 66 | 1730 | 39.9 | 14 | No | Yes | Yes | Yes | pT1b, N1b, M0 | sMTC | 88.3 | 1.8 | No |
| #20 | F | 49 | 2815 | 44.2 | 41 | No | No | Yes | Yes | pT3a, N1b, M0 | FMTC | 375 | 5.0 | No |
| #4 | M | 55 | 2996 | 13.0 | 19 | No | No | Yes | Yes | pT1b, N1b, M0 | MEN2A | 485 | 4.2 | No |
| #39 | F | 61 | 3145 | N/A | 26 | No | No | No | Yes | pT2, N1a, M0 | sMTC | 16.1 | 2.7 | No |
| #3 | M | 46 | 9916 | 339 | 21 | No | No | Yes | Yes | pT2, N1b, M0 | sMTC | 184 | 7.5 | No |
| #40 | M | 60 | 13540 | 152 | 65 | Yes | No | No | No | pT3a, N0, M0 | sMTC | < 2 | 4.3 | Yes |
AJCC TNM, American Joint Committee on Cancer Tumor-Node-Metastases; CEA, carcinoembrion antigen; Ctn, calcitonin; ETE, extrathyroid extension; FMTC, familial medullary thyroid carcinoma; MEN2A, multiple endocrine neoplasia type 2A; N/A not assessed; sMTC, sporadic medullary thyroid carcinoma; Yrs, years.